← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePhase 2
Umbilical Cord Blood-Derived Lymphocyte Therapy (Umbilical Cord Blood-Derived Lymphocyte Therapy)
M.D. Anderson Cancer Center·Plasma Cell Leukemia
7 trials
Overview
Program
Umbilical Cord Blood-Derived Lymphocyte Therapy
Overview
Company
M.D. Anderson Cancer Center
Overview
Modality
CGT
Overview
Target
Plasma Cell Leukemia
Overview
Indication
Plasma Cell Leukemia; Plasma Cell Myeloma
Overview
Phase
PHASE_2
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Emerging
Overview
Approval status
Investigational
Toxicology
Major finding
iPSC-derived modeling of HLA-lacking hematopoiesis reveals clonal diversity in eltrombopag response in acquired aplastic anemia.. Acquired aplastic anemia (AA) is an immune-mediated bone marrow failure in which cytotoxic T lymphocytes (CTLs) target hematopoietic stem cells (HSCs). Approximately 30% of AA patients develop immune escape clones lacking specific HLA class I alleles (HLA[-]) through lo…
Toxicology
CRS
Reported
Clinical
Safety signal
iPSC-derived modeling of HLA-lacking hematopoiesis reveals clonal diversity in eltrombopag response in acquired aplastic anemia.. Acquired aplastic anemia (AA) is an immune-mediated bone marrow failure in which cytotoxic T lymphocytes (CTLs) target hematopoietic stem cells (HSCs). Approximately 30% of AA patients develop immune escape clones lacking specific HLA class I alleles (HLA[-]) through lo…
Clinical
Program phase
PHASE_2